Yuza Kizuki, Nakajima Masato, Nagahashi Masayuki, Tsuchida Junko, Hirose Yuki, Miura Kohei, Tajima Yosuke, Abe Manabu, Sakimura Kenji, Takabe Kazuaki, Wakai Toshifumi
Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Niigata, Japan.
Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Niigata, Japan.
J Surg Res. 2018 Dec;232:186-194. doi: 10.1016/j.jss.2018.06.019. Epub 2018 Jul 6.
Pancreatic cancer is a disease with poor prognosis, and development of new treatments is necessary. Sphingosine-1-phosphate (S1P), a bioactive lipid mediator produced by sphingosine kinases (SphK1 and SphK2), plays a critical role in progression of many types of cancer. However, little is known about the role of sphingosine kinases in pancreatic cancer. This study investigated the roles of sphingosine kinases in pancreatic cancer progression.
S1P levels in pancreatic cancer and noncancerous pancreatic tissue were measured in 10 patients. We generated PAN02 murine pancreatic cancer cell lines with a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated system genes 9 (Cas9)-mediated deletion of SphK1 or SphK2 and assessed cell growth and migration. In an animal model, we assessed the survival of mice injected with PAN02 cells intraperitoneally.
S1P levels in the pancreatic cancer tissue were significantly higher than those in noncancerous tissue. SphK1 knockout (KO) cells showed greater proliferation and migration than wild type (WT) cells, and SphK2 KO cells showed less proliferation and migration than WT cells. Animal experiments showed that the survival of mice injected with SphK1 KO cells was significantly shorter than those injected with WT cells, and the survival of mice injected with SphK2 KO cells was longer than those injected with WT cells. Surprisingly, cytotoxic assay using gemcitabine showed that SphK1 KO cells survived less than WT cells, and SphK2 KO cells survived more than WT cells.
S1P produced by SphK1 and SphK2 may have different functions in pancreatic cancer cells. Targeting both SphK1 and SphK2 may be a potential strategy for pancreatic cancer treatment.
胰腺癌是一种预后较差的疾病,因此开发新的治疗方法很有必要。鞘氨醇-1-磷酸(S1P)是一种由鞘氨醇激酶(SphK1和SphK2)产生的生物活性脂质介质,在多种癌症的进展中起关键作用。然而,关于鞘氨醇激酶在胰腺癌中的作用知之甚少。本研究调查了鞘氨醇激酶在胰腺癌进展中的作用。
测量了10例患者胰腺癌组织和非癌胰腺组织中的S1P水平。我们利用成簇规律间隔短回文重复序列(CRISPR)/CRISPR相关系统基因9(Cas9)介导的SphK1或SphK2缺失,构建了PAN02小鼠胰腺癌细胞系,并评估细胞生长和迁移情况。在动物模型中,我们评估了腹腔注射PAN02细胞的小鼠的生存期。
胰腺癌组织中的S1P水平显著高于非癌组织。SphK1基因敲除(KO)细胞比野生型(WT)细胞表现出更强的增殖和迁移能力,而SphK2 KO细胞比WT细胞表现出较弱的增殖和迁移能力。动物实验表明,注射SphK1 KO细胞的小鼠生存期明显短于注射WT细胞的小鼠,而注射SphK2 KO细胞的小鼠生存期长于注射WT细胞的小鼠。令人惊讶的是,使用吉西他滨的细胞毒性试验表明,SphK1 KO细胞比WT细胞存活更少,而SphK2 KO细胞比WT细胞存活更多。
SphK1和SphK2产生的S1P在胰腺癌细胞中可能具有不同功能。同时靶向SphK1和SphK2可能是一种潜在的胰腺癌治疗策略。